MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content and market expertise into new technology platforms, customer applications and services. The strategic shift, announced via Media OutReach Newswire, marks a significant evolution for a company anchored by six decades of trusted medical data and expertise.
Following the appointment of Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. The company is now ready to harness its data, technology and healthcare relationships to create scalable products and new business models across markets. This matters because it signals a broader trend: traditional healthcare information providers are moving beyond static content to dynamic, tech-enabled solutions that can improve clinical workflows and patient outcomes.
Central to this transformation is the launch of MIMS Pulse, a next-generation Clinical Decision Support platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment and integration capabilities. Alongside MIMS Pulse, the company is scaling eMIMS Plus, a platform that brings MIMS' trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia, eMIMS Plus is now available in India and Malaysia with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent. MIMS is also developing its global CDS offering, building on these platforms to take its clinical data and technology capabilities into new markets and customer environments.
The implications are substantial. By integrating AI and modern deployment capabilities, MIMS aims to support safer and more efficient clinical decision-making at the point of care. This could reduce medication errors, streamline workflows, and ultimately enhance patient safety across diverse healthcare settings. For healthcare professionals, it means access to trusted information in more intuitive, integrated formats.
Simultaneously, MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organizations. The business continues to develop digital events, AI-enabled content capabilities and new customer engagement models. MIMS is exploring more connected, intelligence-led services – helping healthcare and life sciences organizations better understand their markets, engage healthcare professionals and make more informed decisions. This represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services.
Goswami said: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. We have been reshaping the business – bringing our capabilities together, strengthening our technology and building new ways to serve customers across markets. Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products, platforms and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve."
The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities and reach into new areas of healthcare. For an industry increasingly driven by data and digital innovation, MIMS' move underscores the growing importance of leveraging trusted medical information to create scalable, AI-enabled solutions. As healthcare systems worldwide grapple with complexity and cost pressures, such platforms could play a critical role in supporting evidence-based care and operational efficiency. More information is available at https://corporate.mims.com/.
